I en undergruppe analyse var det mere sandsynligt, at patienter med totalt IgE ≥76 IU/ ml før behandling oplevede klinisk betydningsfuld fordel ved Xolair.
In a subgroup analysis patients with pre-treatment total IgE ≥ 76 IU/ ml were more likely to experience clinically meaningful benefit to Xolair.